OCX Quote, Financials, Valuation and Earnings

Fonar has a net margin of -2255.11% compared to OncoCyte's net margin of 7.87%. OncoCyte's return on equity of -581.11% beat Fonar's return on equity of 4.95%.

OncoCyte has a consensus price target of $4.42, signalling upside risk potential of 28.39%. On the other hand Fonar has an analysts' consensus of -- which suggests that it could fall by --. Given that OncoCyte has higher upside potential than Fonar, analysts believe OncoCyte is more attractive than Fonar.

OncoCyte has a beta of 0.973, which suggesting that the stock is 2.709% less volatile than S&P 500. In comparison Fonar has a beta of 1.167, suggesting its more volatile than the S&P 500 by 16.736%.

OncoCyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fonar offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OncoCyte pays -- of its earnings as a dividend. Fonar pays out -- of its earnings as a dividend.

OncoCyte quarterly revenues are $1.5M, which are smaller than Fonar quarterly revenues of $25M. OncoCyte's net income of -$33.5M is lower than Fonar's net income of $2M. Notably, OncoCyte's price-to-earnings ratio is -- while Fonar's PE ratio is 10.45x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OncoCyte is 23.89x versus 0.76x for Fonar. Usually stocks with elevated PS ratios are considered overvalued.

ProPhase Labs has a net margin of -2255.11% compared to OncoCyte's net margin of -209.38%. OncoCyte's return on equity of -581.11% beat ProPhase Labs's return on equity of -59.59%.

OncoCyte has a consensus price target of $4.42, signalling upside risk potential of 28.39%. On the other hand ProPhase Labs has an analysts' consensus of $13.80 which suggests that it could grow by 3640.85%. Given that ProPhase Labs has higher upside potential than OncoCyte, analysts believe ProPhase Labs is more attractive than OncoCyte.

OncoCyte has a beta of 0.973, which suggesting that the stock is 2.709% less volatile than S&P 500. In comparison ProPhase Labs has a beta of -0.562, suggesting its less volatile than the S&P 500 by 156.182%.

OncoCyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProPhase Labs offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OncoCyte pays -- of its earnings as a dividend. ProPhase Labs pays out -- of its earnings as a dividend.

OncoCyte quarterly revenues are $1.5M, which are smaller than ProPhase Labs quarterly revenues of $3.1M. OncoCyte's net income of -$33.5M is lower than ProPhase Labs's net income of -$6.6M. Notably, OncoCyte's price-to-earnings ratio is -- while ProPhase Labs's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OncoCyte is 23.89x versus 1.12x for ProPhase Labs. Usually stocks with elevated PS ratios are considered overvalued.

Veracyte has a net margin of -2255.11% compared to OncoCyte's net margin of 4.31%. OncoCyte's return on equity of -581.11% beat Veracyte's return on equity of 2.14%.

OncoCyte has a consensus price target of $4.42, signalling upside risk potential of 28.39%. On the other hand Veracyte has an analysts' consensus of $42.20 which suggests that it could grow by 30.93%. Given that Veracyte has higher upside potential than OncoCyte, analysts believe Veracyte is more attractive than OncoCyte.

OncoCyte has a beta of 0.973, which suggesting that the stock is 2.709% less volatile than S&P 500. In comparison Veracyte has a beta of 2.032, suggesting its more volatile than the S&P 500 by 103.174%.

OncoCyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Veracyte offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OncoCyte pays -- of its earnings as a dividend. Veracyte pays out -- of its earnings as a dividend.

OncoCyte quarterly revenues are $1.5M, which are smaller than Veracyte quarterly revenues of $118.6M. OncoCyte's net income of -$33.5M is lower than Veracyte's net income of $5.1M. Notably, OncoCyte's price-to-earnings ratio is -- while Veracyte's PE ratio is 107.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OncoCyte is 23.89x versus 5.62x for Veracyte. Usually stocks with elevated PS ratios are considered overvalued.

XWELL has a net margin of -2255.11% compared to OncoCyte's net margin of -56.4%. OncoCyte's return on equity of -581.11% beat XWELL's return on equity of -71.82%.

OncoCyte has a consensus price target of $4.42, signalling upside risk potential of 28.39%. On the other hand XWELL has an analysts' consensus of -- which suggests that it could grow by 800.79%. Given that XWELL has higher upside potential than OncoCyte, analysts believe XWELL is more attractive than OncoCyte.

OncoCyte has a beta of 0.973, which suggesting that the stock is 2.709% less volatile than S&P 500. In comparison XWELL has a beta of 2.106, suggesting its more volatile than the S&P 500 by 110.579%.

OncoCyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XWELL offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OncoCyte pays -- of its earnings as a dividend. XWELL pays out -- of its earnings as a dividend.

OncoCyte quarterly revenues are $1.5M, which are smaller than XWELL quarterly revenues of $8.4M. OncoCyte's net income of -$33.5M is lower than XWELL's net income of -$4.8M. Notably, OncoCyte's price-to-earnings ratio is -- while XWELL's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OncoCyte is 23.89x versus 0.11x for XWELL. Usually stocks with elevated PS ratios are considered overvalued.